| ObjectiveIn this randomized perspective parallel comparison study, in order to assess the efficacy of HTUPA for thrombolysis therapy of acute ST-segment elevation myocardial infarction (ASTEMI), the infarction related coronary artery patency rate and myocardial tissue perfusion of infarction area assessed by coronary angiography (CAG) 90 minutes and indirect indexes of coronary artery recanalization after infusion of HTUPA or recombinant tissue plasminogen activitor (rt-PA)。Acute complications and aderse events after administration of the two medicines were observed for evaluating the safty of HTUPA for ASTEMI thrombolysis and providing evidence for its clinic use.Methodspatients from our hospital who had diagnosed ASTEMI according to the ACC/AHA criteria without thrombolysis contraindications were randomized to HTUPA group and rt-PA group, and they will be teated by HTUPA or rt-PA; After treated with HTUPA or rt-PA for 90minutes, CAG shoud be done.ResultsRecently,80 patients were admitted to this trial which contains Ha trial of 16 patients andⅡb tial of 64 patients; they were all done with CAG. Conclusion:1,25mg HTUPA proved to be as effective as 100mg rt-PA for ASTEMI in the infarction related coronary artery patency.2,The safety of HTUPA thrombolysis therapy is at about the same level of that of rt-PA, not associate with excesses mortality and complications of arrhythmia, heart failure.3,HTUPA is a thrombolysis medicine which was used easily and didn't need continous infusion.Conclusions1.HTUPA proved to be as effective as 1 OOmg rt-PA for ASTEMI in the infarction relately coronary artery patency rate.2.The safety of HTUPA thrombolysis therapy is at about the same level of that of rt-PA, not associate with exessess mortality and complications arrhythmia, heart failure and hemorrhage.3.HTUPA is a thrombolytic medicine which was used easily and didn't need continous infusion. |
PDF Full Text Request